Media Release – SN

NEWSROOM Stay current with MiRXES Newsroom > Media Releases Mirxes receives FDA’s Breakthrough Device Designation for GASTROClearTM to advance blood-based cancer early detection SINGAPORE, 10 August 2023 – Mirxes Corporation USA, the wholly owned subsidiary of Mirxes Pte Ltd, a Singapore-headquartered RNA technology company that is making diagnostic solutions for the early detection of diseases …

Mirxes receives FDA’s Breakthrough Device Designation for GASTROClear to advance blood-based cancer early detection Read More »

NEWSROOM Stay current with MiRXES Newsroom > Media Releases Mirxes secures US$50 Million in Series D funding and files listing application with The Stock Exchange of Hong Kong Limited SINGAPORE, 25 July 2023 – Mirxes Holding Company Limited, a Singapore-headquartered RNA technology company that is making diagnostic solutions for the early detection of diseases accessible …

Mirxes secures US$50 Million in Series D funding and files listing application with The Stock Exchange of Hong Kong Limited Read More »

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES and PT ELION inked landmark MOU to develop blood-based multi-cancer early detection solutions optimized for the Indonesian population SINGAPORE, 29 November 2022 – MiRXES Pte Ltd, a Singapore-headquartered RNA technology company focused on saving lives and improving health economics and outcomes through disease early detection …

MiRXES and PT ELION inked landmark MOU to develop blood-based multi-cancer early detection solutions optimized for the Indonesian population Read More »

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES Unveiled APAC’s First T10 Ultra-high Throughput Sequencing Platform The T10 sequencing platform will provide a significant boost to Singapore’s sequencing power and build a high-resolution spatial transcriptomics pipeline in Singapore SINGAPORE, 22 November 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on saving …

MiRXES Unveiled APAC’s First T10 Ultra-high Throughput Sequencing Platform Read More »

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES collaborates with Plug and Play to launch Southeast Asia’s first science-backed commercialization engine and validator program MiRXES Translator Program will accelerate revenue growth of start-ups and importantly, adoption of preventive healthcare solutions globally SINGAPORE, 25 October 2022 – MiRXES, a Singapore-headquartered biotechnology company focused on …

MiRXES collaborates with Plug and Play to launch Southeast Asia’s first science-backed commercialization engine and validator program Read More »

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES collaborates with NUHCS and NHCS to launch Southeast Asia’s first Asian-focused multi-center study to advance pulmonary hypertension early detection Singapore-headquartered biotech MiRXES, NUHCS and NHCS launch SPHERE study to identify biomarkers that are relevant to early detection of pulmonary hypertension with the aim to improve …

MiRXES collaborates with NUHCS and NHCS to launch Southeast Asia’s first Asian-focused multi-center study to advance pulmonary hypertension early detection Read More »

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES Donates SG$88,902 to NCIS Cancer Fund through Let’s Ride! Singapore Closing Ride SINGAPORE, 18 September 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection …

MiRXES Donates SG$88,902 to NCIS Cancer Fund through Let’s Ride! Singapore Closing Ride Read More »

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES strengthens global fight against cancer with launch of world’s first research project for a multi-cancer screening test using microRNA and multi-omics technology SINGAPORE, 7 July 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, …

Project CADENCE MOU Signing Read More »

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES – BGI Research – MGI Strategic Partnership to Scale Cutting-Edge Spatial Multi-Omics Research Capabilities in Asia-Pacific Region SINGAPORE, 7 June 2022 – MiRXES, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses, announced today that it …

MiRXES–BGI Research–MGI Strategic Partnership Read More »

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES Opens Southeast Asia’s First Industry 4.0 In Vitro Diagnostic Manufacturing Facility Singapore, 27 May 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, and A*STAR spinoff, focused on saving and improving lives with miRNA-powered cancer early detection tests, announced today the opening of the first …

MiRXES Opens Southeast Asia’s First Industry 4.0 In Vitro Diagnostic Manufacturing Facility Read More »